Nxera Pharma Co., Ltd.
SOLTF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$4,662,000 | -$7,193,000 | $1,078,000 | $433,000 |
| Dep. & Amort. | $3,984,000 | $2,478,000 | $1,345,000 | $1,278,000 |
| Deferred Tax | $0 | $0 | $2,361,000 | $2,647,000 |
| Stock-Based Comp. | $1,396,000 | $870,000 | $700,000 | $713,000 |
| Change in WC | -$6,024,000 | $1,609,000 | $5,258,000 | -$1,783,000 |
| Other Non-Cash | -$2,412,000 | -$3,037,000 | -$790,000 | $3,807,000 |
| Operating Cash Flow | -$7,718,000 | -$5,273,000 | $9,952,000 | $7,095,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$526,000 | -$804,000 | -$303,000 | -$201,000 |
| Net Acquisitions | $379,000 | -$62,941,000 | $137,000 | $206,000 |
| Inv. Purchases | $0 | $0 | $26,000 | -$206,000 |
| Inv. Sales/Matur. | $0 | $0 | $1,209,000 | $206,000 |
| Other Inv. Act. | -$4,616,000 | -$46,000 | -$26,000 | $273,000 |
| Investing Cash Flow | -$4,763,000 | -$63,791,000 | $1,043,000 | $278,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$5,950,000 | $38,858,000 | $0 | $10,897,000 |
| Stock Issued | $0 | $9,983,000 | $0 | $600,000 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$904,000 | -$512,000 | -$4,887,000 | -$374,000 |
| Financing Cash Flow | -$6,854,000 | $48,329,000 | -$4,887,000 | $11,123,000 |
| Forex Effect | $2,538,000 | $3,243,000 | $362,000 | $1,583,000 |
| Net Chg. in Cash | -$16,797,000 | -$17,492,000 | $6,470,000 | $20,079,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $49,065,000 | $66,557,000 | $60,087,000 | $40,008,000 |
| End Cash | $32,268,000 | $49,065,000 | $66,557,000 | $60,087,000 |
| Free Cash Flow | -$9,255,000 | -$6,124,000 | $9,649,000 | $6,894,000 |